FIELD: medicine.
SUBSTANCE: present invention relates to pulmonology, and discloses use of a liquid pharmaceutical composition for treating a disease or condition in a subject representing chronic obstructive pulmonary disease (COPD) or asthma, suitable for administration by inhalation, comprising: (i) a suspension of particles containing 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) and (ii) a diluent which is 1,1,1,2-tetrafluoroethane (HFA-134a), wherein the liquid pharmaceutical composition contains less than 0.05 wt.% of a surfactant based on the total weight of the composition.
EFFECT: providing favourable suspension characteristics and reduced flocculation, as well as providing a chemically and physically stable composition without the need for surfactants which increase the risk of an allergic inflammatory reaction.
16 cl, 5 dwg, 11 tbl, 4 ex
